Last reviewed · How we verify
Ivabradine (Procoralan)
Ivabradine selectively inhibits the funny current (If) in the sinoatrial node, reducing heart rate without affecting blood pressure or cardiac contractility.
Ivabradine selectively inhibits the If (funny) current in the sinoatrial node, reducing heart rate without affecting blood pressure or cardiac contractility. Used for Chronic heart failure with reduced ejection fraction (HFrEF) in patients with elevated heart rate, Angina pectoris in patients unable to tolerate or contraindicated for beta-blockers.
At a glance
| Generic name | Ivabradine (Procoralan) |
|---|---|
| Sponsor | Medical University of Lodz |
| Drug class | If channel inhibitor |
| Target | HCN channel (hyperpolarization-activated cyclic nucleotide-gated channel) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Ivabradine acts as a selective inhibitor of the hyperpolarization-activated cyclic nucleotide-gated (HCN) channel, specifically blocking the funny current that regulates the spontaneous diastolic depolarization in pacemaker cells. This mechanism reduces heart rate in a use-dependent manner, making it particularly useful in patients with elevated resting heart rate. Unlike beta-blockers, it does not affect atrioventricular conduction or myocardial contractility.
Approved indications
- Chronic heart failure with reduced ejection fraction and elevated heart rate
- Stable angina pectoris
Common side effects
- Bradycardia
- Phosphenes (visual symptoms)
- Atrial fibrillation
- Luminopsia
Key clinical trials
- Ivabradine for Heart Rate Control In Septic Shock (PHASE3)
- De-Adoption of Beta-Blockers in Patients With Stable Ischemic Heart Disease (PHASE4)
- RECOVER-AUTONOMIC Platform Protocol (PHASE2)
- RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine) (PHASE2)
- Effect of Pharmacological Heart Rate Reduction on Visco-elastic Properties of the Arterial Wall (BRADYVASC) (PHASE3)
- Effect of Ivabradine on Levcromakalim-Induced Symptoms in Individuals With Migraine Without Aura (ILIM) (NA)
- Heart Rate Control Before Cardiac Computed Tomography in Adults for the Evaluation of Coronary Artery Disease (PHASE2, PHASE3)
- Ivabradine for Prevention of Myocardial Injury After Noncardiac Surgery Trial (PREVENT-MINS) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ivabradine (Procoralan) CI brief — competitive landscape report
- Ivabradine (Procoralan) updates RSS · CI watch RSS
- Medical University of Lodz portfolio CI